This study is testing a new medicine called **TOUR006** for people with **chronic kidney disease** (CKD) who have high levels of **hs-CRP**. CKD means the kidneys are damaged and don’t work as well as they should. Hs-CRP is a marker in the blood that shows inflammation, which is when the body is fighting something like an illness. TOUR006 is a type of medicine called a **monoclonal antibody** that helps reduce inflammation by blocking a protein called **IL-6**. The study will check if TOUR006 is safe and how it affects hs-CRP levels when given under the skin either every month or every three months.

• Participants must be at least 18 years old and have been vaccinated for COVID-19 at least 30 days before starting the study.
• People with recent or serious infections, or certain heart problems, cannot join.
• The study will include multiple visits and requires participants to follow certain health guidelines.

It’s important to talk to your doctor to see if this study is a good fit for you, especially considering the visits and health requirements involved.